EP1072270B1 - Toxine de Botulinum pour le traitement de la dystonie - Google Patents
Toxine de Botulinum pour le traitement de la dystonie Download PDFInfo
- Publication number
- EP1072270B1 EP1072270B1 EP00203294A EP00203294A EP1072270B1 EP 1072270 B1 EP1072270 B1 EP 1072270B1 EP 00203294 A EP00203294 A EP 00203294A EP 00203294 A EP00203294 A EP 00203294A EP 1072270 B1 EP1072270 B1 EP 1072270B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- botulinum
- dystonia
- botulinum toxin
- medicament
- type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the present invention provides treatments for dystonia using botulinum toxin type B.
- Botulinum toxins in particular Botulinum toxin type A, has been used in the treatment of a number of neuromuscular disorders and conditions involving muscular spasm; for example, strabismus, blepharospasm, spasmodic torticollis (cervical dystonia), oromandibular dystonia and spasmodic dysphonia (laryngeal dystonia).
- the toxin binds rapidly and strongly to presynaptic cholinergic nerve terminals and inhibits the exocytosis of acetylcholine by decreasing the frequency of acetylcholine release. This results in local paralysis and hence relaxation of the muscle afflicted by spasm.
- Botulinum toxin is a generic term embracing the family of toxins produced by the anaerobic bacterium Clostridium botulinum and, to date, seven immunologically distinct neurotoxins have been identified. These have been given the designations A, B, C, D, E, F and G.
- Botulinum toxin is a generic term embracing the family of toxins produced by the anaerobic bacterium Clostridium botulinum and, to date, seven immunologically distinct neurotoxins have been identified. These have been given the designations A, B, C, D, E, F and G.
- the neurotoxic component of Botulinum toxin has a molecular weight of about 150 kilodaltons and is thought to comprise a short polypeptide chain of about 50 kD which is considered to be responsible for the toxic properties of the toxin, i.e., by interfering with the exocytosis of acetylcholine, by decreasing the frequency of acetylcholine release, and a larger polypeptide chain of about 100 kD which is believed to be necessary to enable the toxin to bind to the presynaptic membrane.
- the “short” and “long” chains are linked together by means of a simple disulfide bridge.
- certain serotypes of Botulinum toxin e.g., type E
- the single chain form is less active but may be converted to the corresponding dichain by nicking with a protease, e.g., trypsin. Both the single and the dichain are useful in the method of the present invention.
- C. botulinum In general, four physiologic groups of C. botulinum are recognized (I, II, III, IV).
- the organisms capable of producing a serologically distinct toxin may come from more than one physiological group.
- Type B and F toxins can be produced by strains from Group I or II.
- other strains of clostridial species C. baratii, type F; C. butyricum, type E; C. novyi, type C 1 or D
- C. baratii, type F; C. butyricum, type E; C. novyi, type C 1 or D have been identified which can produce botulinum neurotoxins.
- Immunotoxin conjugates of ricin and antibodies which are characterized as having enhanced cytotoxicity through improving cell surface affinity, are disclosed in European Patent Specification 0 129 434.
- the inventors note that botulinum toxin may be utilized in place of ricin.
- Botulinum toxin is obtained commercially by establishing and growing cultures of C. botulinum in a fermenter and then harvesting and purifying the fermented mixture in accordance with known techniques.
- Botulinum toxin type A the toxin type generally utilized in treating neuromuscular conditions, is currently available commercially from several sources; for example, from Porton Products Ltd. UK, under the trade name "DYSPORT,” and from Allergan, Inc., Irvine, California, under the trade name BOTOX®.
- Each serotype of Botulinum toxin has been identified as immunologically different proteins through the use of specific antibodies. For example, if the antibody (antitoxin) recognizes, that is, neutralizes the biological activity of, for example, type A it will not recognize types B, C, D, E, F or G.
- Botulinum toxins appear to be zinc endopeptidases
- the mechanism of action of different serotypes, for example, A and E within the neuron appear to be different than that of Type B.
- the neuronal surface "receptor" for the toxin appears to be different for the serotypes.
- Botulinum toxins in accordance with the present invention with regard to organ systems which involve the release of neurotransmitter, it is expected to introduce the toxins B, directly by local injections.
- the Botulinum toxin used according to the present invention is Botulinum toxin type B.
- Clostridium botulinum types are listed in Table I. Physiologic Groups or Clostridium botulinum Group Toxin Sero-Type Biochemistry Milk Digest Glucose Fermentation Lipase Phages & Plasmids Phenotypically Related Clostridium (nontoxigenic) I A,B,F proteolytic saccharolytic + + + + C. sporogenes II B,E,F nonproteolytic saccharolytic psychotropic - + + + III C,D nonproteolytic saccharolytic + + + + + C. novyi IV G proteolytic nonsaccharolytic + - - - C.
- toxin types may be produced by selection from the appropriate physiologic group of Clostridium botulinum organisms.
- the organisms designated as Group I are usually referred to as proteolytic and produce Botulinum toxins of types A, B and F.
- the organisms designated as Group II are saccharolytic and produce Botulinum toxins of types B, E and F.
- the organisms designated as Group III produce only Botulinum toxin types C and D and are distinguished from organisms of Groups I and II by the production of significant amounts of propionic acid.
- Group IV organisms only produce neurotoxin of type G.
- Botulinum toxin types A, B, C, D, E, F and G are described in Chapter 1 of Botulinum Neurotoxin and Tetanus Toxin, cited above, and/or the references cited therein.
- Botulinum toxins types B, C, D, E, F and G are also available from various species of clostridia.
- Organisms which produce Botulinum toxins have been isolated from botulism outbreaks in humans (types A, B, E and F) and animals (types C and D). Their identities were described through the use of specific antitoxins (antibodies) developed against the earlier toxins.
- Type G toxin was found in soil and has low toxigenicity. However, it has been isolated from autopsy specimens, but thus far there has not been adequate evidence that type G botulism has occurred in humans.
- the toxin is administered by means of intramuscular injection directly into a local area such as a spastic muscle, preferably in the region of the neuromuscular junction, although alternative types of administration (e.g., subcutaneous injection), which can deliver the toxin directly to the affected region, may be employed where appropriate.
- the toxin can be presented as a sterile pyrogen-free aqueous solution or dispersion and as a sterile powder for reconstitution into a sterile solution or dispersion.
- tonicity adjusting agents such as sodium chloride, glycerol and various sugars can be added.
- Stabilizers such as human serum albumin may also be included.
- the formulation may be preserved by means of a suitable pharmaceutically acceptable preservative such as a paraben, although preferably it is unpreserved.
- the toxin is formulated in unit dosage form; for example, it can be provided as a sterile solution in a vial or as a vial or sachet containing a lyophilized powder for reconstituting a suitable vehicle such as saline for injection.
- the Botulinum toxin is formulated in a solution containing saline and pasteurized human serum albumin, which stabilizes the toxin and minimizes loss through non-specific adsorption.
- the solution is sterile filtered (0.2 micron filter), filled into individual vials and then vacuum-dried to give a sterile lyophilized powder.
- the powder can be reconstituted by the addition of sterile unpreserved normal saline (sodium chloride 0.9% for injection).
- the dose of toxin administered to the patient will depend upon the severity of the condition; e.g., the number of muscle groups requiring treatment, the age and size of the patient and the potency of the toxin.
- the potency of the toxin is expressed as a multiple of the LD 50 value for the mouse, one unit (U) of toxin being defined as being the equivalent amount of toxin that kills 50% of a group of 18 to 20 female Swiss-Webster mice, weighing about 20 grams each.
- the dosages used in human therapeutic applications are roughly proportional to the mass of muscle being injected.
- the dose administered to the patient may be up from about 0.01 to about 1,000 units; for example, up to about 500 units, and preferably in the range from about 80 to about 460 units per patient per treatment, although smaller of larger doses may be administered in appropriate circumstances such as up to about 50 units for the relief of pain and in controlling cholinergic secretions.
- each patient is injected with a sterile solution containing the confirmation of Botulinum toxin.
- Total patient doses range from about 0.01 units to 460 units.
- the aim being to inject the area with the highest concentration of neuromuscular junctions, if known.
- the position of the needle in the muscle is confirmed by putting the muscle through its range of motion and observing the resultant motion of the needle end.
- General anaesthesia, local anaesthesia and sedation are used according to the age of the patient, the number of sites to be injected, and the particular needs of the patient. More than one injection and/or sites of injection may be necessary to achieve the desired result.
- some injections depending on the muscle to be injected, may require the use of fine, hollow, teflon-coated needles, guided by electromyography.
- an antipsychotic drug such as Thorazine or Haldol
- 150 units of Botulinum toxin type B by direct injection of such toxin into the facial muscles.
- the symptoms of tardive dyskinesia i.e., orofacial dyskinesia, athetosis, dystonia, chorea, tics and facial grimacing, etc. are markedly reduced.
- Botulinum toxin Type B in the Treatment of Spasmodic Torticollis
- a patient suffering from spasmodic torticollis, as manifested by spasmodic or tonic contractions of the neck musculature, producing stereotyped abnormal deviations of the head, the chin being rotated to one side, and the shoulder being elevated toward the side at which the head is rotated, is treated by injection with 100-1,000 units of Botulinum toxin type B. After 3-7 days, the symptoms are substantially alleviated; i.e., the patient is able to hold his head and shoulder in a normal position.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Otolaryngology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (6)
- Utilisation de la toxine botulinique de type B pour la fabrication d'un médicament destinée à traiter. la dystonie, à condition que :i) le médicament ne soit pas une préparation séchée et congelée comprenant la neurotoxine de C. botulinum de type B associée à des protéines stabilisantes dérivées botulinique afin de former un complexe, le complexe ayant un poids moléculaire déterminé par chromatographie par perméation de gel d'au moins 300 kD, en mélange avec un excipient pharmaceutiquement acceptable pour maintenir la stabilité du complexe à des concentrations de 104 unités LD50 chez la souris par millilitre ou moins, qui quand elle est reconstituée en solution aqueuse conserve au moins 75 % de son activité toxique, destiné au traitement du torticolis spasmodique, de la dysphonie spastique, du blépharospasme et des dystonies régionales des mains ;ii) le médicament ne soit pas une combinaison de toxines botuliniques de type A et B destinée au traitement de la dyskinésie tardive, du tremblement essentiel, de la dysphonie spastique ou du blépharospasme ; etiii) le médicament ne soit pas destiné à traiter la dyskinésie tardive consécutive à un traitement par la toxine botulinique de type A ou le torticolis spasmodique consécutif à un traitement par le botulinum de type E.
- Utilisation selon la revendication 1 dans laquelle la dystonie est une dyskinésie tardive.
- Utilisation selon la revendication 1 dans laquelle la dystonie est un torticolis spasmodique.
- Utilisation selon la revendication 1 dans laquelle la dystonie est un tremblement essentiel.
- Utilisation selon la revendication 1 dans laquelle la dystonie est une dysphonie spastique.
- Utilisation selon l'un quelconque des revendications précédentes dans laquelle le médicament est destiné à une administration par injection intramusculaire.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07002714A EP1790352B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de la toxine botulique pour la fabrication d'un médicament destiné à réduire la douleur dorsale |
EP01118792A EP1147775B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament à réduire la douleur liée à des troubles musculaires |
EP01118793A EP1147776B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament pour la traitement des spasmes musculaires |
EP05017284A EP1602379A1 (fr) | 1993-12-28 | 1994-12-16 | Toxines de Botulinum B pour le traitement du muscle spastique |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17399693A | 1993-12-28 | 1993-12-28 | |
US173996 | 1993-12-28 | ||
EP95906674A EP0737074B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botulinum utilisees dans le traitement de l'hyperhydrosis |
Related Parent Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95906674A Division EP0737074B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botulinum utilisees dans le traitement de l'hyperhydrosis |
EP95906674.7 Division | 1995-07-06 |
Related Child Applications (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP01118793A Division EP1147776B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament pour la traitement des spasmes musculaires |
EP01118792A Division EP1147775B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament à réduire la douleur liée à des troubles musculaires |
EP01118792.9 Division-Into | 2001-08-09 | ||
EP01118793.7 Division-Into | 2001-08-09 | ||
EP05017284.0 Division-Into | 2005-08-09 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1072270A2 EP1072270A2 (fr) | 2001-01-31 |
EP1072270A3 EP1072270A3 (fr) | 2002-08-07 |
EP1072270B1 true EP1072270B1 (fr) | 2005-10-19 |
Family
ID=22634387
Family Applications (23)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04019048A Revoked EP1488803B1 (fr) | 1993-12-28 | 1994-12-16 | Composante neurotoxique de la toxine botulinique pour la traitement de la dystonie cervicale |
EP04000166A Expired - Lifetime EP1421948B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de toxines botuliniques contre la transpiration chez l'homme |
EP05018367A Expired - Lifetime EP1600163B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour traiter un spasme musculaire |
EP01118792A Expired - Lifetime EP1147775B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament à réduire la douleur liée à des troubles musculaires |
EP05017284A Withdrawn EP1602379A1 (fr) | 1993-12-28 | 1994-12-16 | Toxines de Botulinum B pour le traitement du muscle spastique |
EP97200028A Expired - Lifetime EP0770395B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine de botulinum pour soulager les maux de tête |
EP07002714A Expired - Lifetime EP1790352B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de la toxine botulique pour la fabrication d'un médicament destiné à réduire la douleur dorsale |
EP04018914A Withdrawn EP1486214A1 (fr) | 1993-12-28 | 1994-12-16 | Toxine botulinique pour le traitement des spasmes musculaires |
EP99203735A Expired - Lifetime EP1010431B2 (fr) | 1993-12-28 | 1994-12-16 | Toxines botuliniques A pour le traitement de la douleur liée à des spasmes des muscles lisses |
EP01118793A Expired - Lifetime EP1147776B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament pour la traitement des spasmes musculaires |
EP00203421A Revoked EP1103267B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botuliniques utilisées dans le traitement de douleurs associées à des maladies musculaires |
EP04019047A Revoked EP1477183B1 (fr) | 1993-12-28 | 1994-12-16 | Composante neurotoxique de la toxine botulinique pour la modulation des secretions controllées par le système cholinergique |
EP08017803A Expired - Lifetime EP2027872B1 (fr) | 1993-12-28 | 1994-12-16 | Composant neurotoxique d'une toxine botulique pour traiter la dyskinésie tardive |
EP03015589A Revoked EP1366770B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de la douleur liée à des troubles musculaires |
EP99203920A Expired - Lifetime EP1005867B2 (fr) | 1993-12-28 | 1994-12-16 | Toxines de botulinum pour la modulation des secretions controlées par le système cholinergique |
EP06016208A Expired - Lifetime EP1757325B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de la toxine botulinique pour traiter les douleurs myofasciales |
EP04019046A Expired - Lifetime EP1502600B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de maladies liées aux muscles lisses |
EP00203294A Expired - Lifetime EP1072270B1 (fr) | 1993-12-28 | 1994-12-16 | Toxine de Botulinum pour le traitement de la dystonie |
EP05018368A Expired - Lifetime EP1598077B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour traiter un spasme musculaire |
EP05016177A Expired - Lifetime EP1591129B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de la douleur liée à la dystonie cervicale |
EP95906674A Expired - Lifetime EP0737074B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botulinum utilisees dans le traitement de l'hyperhydrosis |
EP03015590A Revoked EP1366771B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires |
EP05006665.3A Expired - Lifetime EP1563843B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botuliniques utilisées dans le traitement de maladies musculaires |
Family Applications Before (17)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04019048A Revoked EP1488803B1 (fr) | 1993-12-28 | 1994-12-16 | Composante neurotoxique de la toxine botulinique pour la traitement de la dystonie cervicale |
EP04000166A Expired - Lifetime EP1421948B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de toxines botuliniques contre la transpiration chez l'homme |
EP05018367A Expired - Lifetime EP1600163B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour traiter un spasme musculaire |
EP01118792A Expired - Lifetime EP1147775B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament à réduire la douleur liée à des troubles musculaires |
EP05017284A Withdrawn EP1602379A1 (fr) | 1993-12-28 | 1994-12-16 | Toxines de Botulinum B pour le traitement du muscle spastique |
EP97200028A Expired - Lifetime EP0770395B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine de botulinum pour soulager les maux de tête |
EP07002714A Expired - Lifetime EP1790352B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de la toxine botulique pour la fabrication d'un médicament destiné à réduire la douleur dorsale |
EP04018914A Withdrawn EP1486214A1 (fr) | 1993-12-28 | 1994-12-16 | Toxine botulinique pour le traitement des spasmes musculaires |
EP99203735A Expired - Lifetime EP1010431B2 (fr) | 1993-12-28 | 1994-12-16 | Toxines botuliniques A pour le traitement de la douleur liée à des spasmes des muscles lisses |
EP01118793A Expired - Lifetime EP1147776B1 (fr) | 1993-12-28 | 1994-12-16 | L'utilisation de la toxine botulinique type B pour la préparation d'un médicament pour la traitement des spasmes musculaires |
EP00203421A Revoked EP1103267B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botuliniques utilisées dans le traitement de douleurs associées à des maladies musculaires |
EP04019047A Revoked EP1477183B1 (fr) | 1993-12-28 | 1994-12-16 | Composante neurotoxique de la toxine botulinique pour la modulation des secretions controllées par le système cholinergique |
EP08017803A Expired - Lifetime EP2027872B1 (fr) | 1993-12-28 | 1994-12-16 | Composant neurotoxique d'une toxine botulique pour traiter la dyskinésie tardive |
EP03015589A Revoked EP1366770B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de la douleur liée à des troubles musculaires |
EP99203920A Expired - Lifetime EP1005867B2 (fr) | 1993-12-28 | 1994-12-16 | Toxines de botulinum pour la modulation des secretions controlées par le système cholinergique |
EP06016208A Expired - Lifetime EP1757325B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation de la toxine botulinique pour traiter les douleurs myofasciales |
EP04019046A Expired - Lifetime EP1502600B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de maladies liées aux muscles lisses |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP05018368A Expired - Lifetime EP1598077B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour traiter un spasme musculaire |
EP05016177A Expired - Lifetime EP1591129B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour le traitement de la douleur liée à la dystonie cervicale |
EP95906674A Expired - Lifetime EP0737074B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botulinum utilisees dans le traitement de l'hyperhydrosis |
EP03015590A Revoked EP1366771B1 (fr) | 1993-12-28 | 1994-12-16 | Utilisation du composant neurotoxique de la toxine botulinique pour traiter les spasmes musculaires |
EP05006665.3A Expired - Lifetime EP1563843B1 (fr) | 1993-12-28 | 1994-12-16 | Toxines botuliniques utilisées dans le traitement de maladies musculaires |
Country Status (9)
Country | Link |
---|---|
EP (23) | EP1488803B1 (fr) |
JP (33) | JP3238154B2 (fr) |
AU (1) | AU688452B2 (fr) |
CA (2) | CA2682117A1 (fr) |
DE (23) | DE69435276D1 (fr) |
ES (18) | ES2247575T3 (fr) |
FR (1) | FR08C0034I1 (fr) |
HK (6) | HK1033274A1 (fr) |
WO (1) | WO1995017904A2 (fr) |
Families Citing this family (102)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9120306D0 (en) | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
DE69435254D1 (de) | 1993-06-10 | 2009-12-31 | Allergan Inc | Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen |
US6974578B1 (en) | 1993-12-28 | 2005-12-13 | Allergan, Inc. | Method for treating secretions and glands using botulinum toxin |
AU688452B2 (en) * | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
US8557256B2 (en) | 1993-12-28 | 2013-10-15 | Allergan, Inc. | Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin |
US8187612B2 (en) | 1993-12-28 | 2012-05-29 | Allergan, Inc. | Use of the neurotoxic component of a botulinum toxin for treating a spastic muscle |
AU2007202480B2 (en) * | 1993-12-28 | 2009-01-29 | Allergan, Inc. | Method for treating pain associated with a muscle disorder |
ATE292977T1 (de) * | 1994-05-09 | 2005-04-15 | William J Binder | Präsynaptische neurotoxine gegen migränekopfschmerzen |
US5721215A (en) * | 1996-03-20 | 1998-02-24 | Allergan | Injectable therapy for control of muscle spasms and pain related to muscle spasms |
US6699966B1 (en) | 1996-07-08 | 2004-03-02 | University Of Massachusetts | Proteins within the type E botulinum neurotoxin complex |
US6780413B2 (en) | 1996-09-19 | 2004-08-24 | The United States Of America As Represented By The Department Of Health And Human Services | Immunotoxin (mAB-RICIN) for the treatment of focal movement disorders |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
AU2006225231B2 (en) * | 1997-07-15 | 2006-12-07 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders |
ES2385130T3 (es) * | 1997-07-15 | 2012-07-18 | The Regents Of The University Of Colorado, A Body Corporate | Uso de terapia con neurotoxinas para el tratamiento de enfermedades urológicas y de enfermedades relacionadas |
US7470431B2 (en) | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US9066943B2 (en) | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
AU2008201535C1 (en) * | 1997-07-15 | 2013-09-12 | Allergan, Inc. | Use of neurotoxin therapy for treatment of urologic and related disorders |
US6063768A (en) * | 1997-09-04 | 2000-05-16 | First; Eric R. | Application of botulinum toxin to the management of neurogenic inflammatory disorders |
GB9721189D0 (en) | 1997-10-08 | 1997-12-03 | Speywood Lab The Limited | Analgesic conjugates |
AU2340299A (en) | 1998-01-26 | 1999-08-09 | University Of Massachusetts | Biologically active hemagglutinin from type a (clostridium botulinum) and methods of use |
GB9818548D0 (en) * | 1998-08-25 | 1998-10-21 | Microbiological Res Authority | Treatment of mucas hypersecretion |
US8790897B2 (en) | 1998-08-25 | 2014-07-29 | Syntaxin Ltd. | Treatment of mucus hypersecretion |
US20040071736A1 (en) | 1998-08-25 | 2004-04-15 | Health Protection Agency | Methods and compounds for the treatment of mucus hypersecretion |
TW574036B (en) | 1998-09-11 | 2004-02-01 | Elan Pharm Inc | Stable liquid compositions of botulinum toxin |
DE19856897A1 (de) * | 1998-12-10 | 2000-06-15 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum zur Unterdrückung von Schnarchgeräuschen |
DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US6767544B2 (en) * | 2002-04-01 | 2004-07-27 | Allergan, Inc. | Methods for treating cardiovascular diseases with botulinum toxin |
US6977080B1 (en) * | 1999-08-10 | 2005-12-20 | Allergan, Inc. | Intrapericardial botulinum toxin treatment for bradycardia |
GB9922554D0 (en) | 1999-09-23 | 1999-11-24 | Microbiological Res Authority | Inhibition of secretion from non-neuronal cells |
US6139845A (en) | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6337075B1 (en) | 2000-01-11 | 2002-01-08 | Allergan Sales, Inc. | Methods for treating diabetes |
US6143306A (en) * | 2000-01-11 | 2000-11-07 | Allergan Sales, Inc. | Methods for treating pancreatic disorders |
US6261572B1 (en) | 2000-01-11 | 2001-07-17 | Allergan Sales, Inc. | Method for treating a pancreatic disorder with a neurotoxin |
US6524580B1 (en) * | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6358513B1 (en) * | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6319506B1 (en) * | 2000-02-22 | 2001-11-20 | Allergan, Sales, Inc. | Method for treating hypercalcemia |
US6464986B1 (en) * | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
US6306403B1 (en) | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
AU2001276005A1 (en) * | 2000-08-02 | 2002-02-13 | Allergan Sales, Inc. | Method for treating a neoplasm |
US6423319B1 (en) * | 2000-10-04 | 2002-07-23 | Allergan Sales, Inc. | Methods for treating muscle injuries |
US6827931B1 (en) | 2000-10-20 | 2004-12-07 | Allergan, Inc. | Method for treating endocrine disorders |
US7255865B2 (en) | 2000-12-05 | 2007-08-14 | Allergan, Inc. | Methods of administering botulinum toxin |
US20020086036A1 (en) | 2000-12-05 | 2002-07-04 | Allergan Sales, Inc. | Methods for treating hyperhidrosis |
ITUD20010002A1 (it) | 2001-01-05 | 2002-07-05 | Univ Degli Studi Udine | Uso della tossina botulinica per la soluzione di patologie articolari, in particolare della coxartrosi, della epicondilite e della patolo |
GB0111146D0 (en) * | 2001-05-04 | 2001-06-27 | Imp College Innovations Ltd | Methods |
JP2003009897A (ja) | 2001-07-03 | 2003-01-14 | Keiji Oguma | ボツリヌス毒素の分離・精製法 |
KR20030018827A (ko) * | 2001-08-31 | 2003-03-06 | 서구일 | A형 보툴리눔 독소를 유효성분으로 포함하는 신경차단제,및 이를 이용한 교감신경절 차단의 적응질환 치료제 |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US20030113349A1 (en) | 2001-12-18 | 2003-06-19 | Coleman William P. | Topically applied clostridium botulinum toxin compositions and treatment methods |
US6921538B2 (en) * | 2002-05-10 | 2005-07-26 | Allergan, Inc. | Therapeutic treatments for neuropsychiatric disorders |
US6776991B2 (en) | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
US20040009180A1 (en) * | 2002-07-11 | 2004-01-15 | Allergan, Inc. | Transdermal botulinum toxin compositions |
CA2501856A1 (fr) * | 2002-10-15 | 2004-04-29 | Allergan, Inc. | Therapies et procedures dentaires a base de toxine botulinique |
US7238357B2 (en) | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US20040086532A1 (en) | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
CA2518155A1 (fr) | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Traitment de kystes de meibomius et d'orgelets chroniques avec la toxine botulique |
MXPA05009425A (es) * | 2003-03-06 | 2006-02-10 | Botulinum Toxin Res Ass Inc | Tratamiento del dolor facial cronico y cefalea relacionados con la sinusitis con toxina botulinica. |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
FR2857595B1 (fr) * | 2003-07-18 | 2005-10-07 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour preparer un medicament destine a prevenir ou traiter les troubles sonores lies a l'agonie |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8617572B2 (en) | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US7276244B2 (en) | 2004-02-12 | 2007-10-02 | Philip Radovic | Methods of treating abnormalities of the first metatarsophalangeal joint of the foot |
AU2005215521A1 (en) * | 2004-02-12 | 2005-09-01 | Radovic, Phillip | Treatment of abnormalities of the first metatarsophalangeal joint of the foot |
US20050191321A1 (en) * | 2004-02-26 | 2005-09-01 | Allergan, Inc. | Methods for treating headache |
KR101284710B1 (ko) | 2004-03-03 | 2013-07-23 | 레반스 테라퓨틱스, 아이엔씨. | 국소 진단제 및 치료제의 수송을 위한 조성물 및 방법 |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
CN1946431B (zh) | 2004-03-03 | 2011-12-07 | 雷文斯治疗公司 | 用于肉毒毒素的局部施用和透皮递送的组合物和方法 |
BRPI0608249A2 (pt) | 2005-03-03 | 2009-12-08 | Revance Therapeutics Inc | formulação, método para aplicação tópica e kit para distribuição transdérmica de toxina botulìnica |
EP1747782A1 (fr) | 2005-07-19 | 2007-01-31 | Cesare Montecucco | Produits pour l'application topique comprenant de lysophospholipids et d'acides gras |
US7910116B2 (en) | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
JP4944896B2 (ja) | 2005-11-17 | 2012-06-06 | ルバンス セラピュティックス インク. | 低減された非毒素タンパク質を含むボツリヌス毒素の局所適用及び経皮送達のための組成物及び方法 |
WO2007095486A1 (fr) * | 2006-02-13 | 2007-08-23 | Allergan, Inc. | Procedes de traitement des blepharospasmes reposant sur des composants de cyclosporine |
US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
US7811586B2 (en) | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
FR2902341B1 (fr) | 2006-06-16 | 2011-02-25 | Scras | Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
FR2907680B1 (fr) * | 2006-10-27 | 2012-12-28 | Scras | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux |
FR2910327B1 (fr) | 2006-12-22 | 2013-04-26 | Scras | Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida. |
WO2008121067A1 (fr) | 2007-03-30 | 2008-10-09 | Anders Fagergren | Quantification des contributions mécaniques et neuronales à la spasticité |
CN101842107B (zh) | 2007-07-26 | 2014-04-23 | 雷文斯治疗公司 | 抗微生物肽,组合物和使用方法 |
EP2072039A1 (fr) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Utilisation d'un composant neurotoxique du complexe de la toxine du Clostridium botulinum pour réduire ou prévenir les effets latéraux |
US8470337B2 (en) | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
FR2930447B1 (fr) | 2008-04-25 | 2010-07-30 | Sod Conseils Rech Applic | Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique |
US20100124559A1 (en) * | 2008-11-20 | 2010-05-20 | Allergan, Inc. | Early Treatment and Prevention of Increased Muscle Tonicity |
SG172812A1 (en) | 2008-12-31 | 2011-08-29 | Revance Therapeutics Inc | Injectable botulinum toxin formulations |
KR102328155B1 (ko) | 2009-06-25 | 2021-11-17 | 레반스 테라퓨틱스, 아이엔씨. | 알부민불포함 보툴리눔 독소 제제 |
US8147848B2 (en) | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
WO2014066916A2 (fr) | 2012-10-28 | 2014-05-01 | Revance Therapeutics, Inc. | Compositions et procédés pour le traitement sûr de la rhinite |
RU2545453C2 (ru) * | 2013-03-21 | 2015-03-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Самарский государственный медицинский университет" Министерства здравоохранения Российской Федерации | Способ лечения переломов нижней челюсти |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
WO2016002984A1 (fr) * | 2014-06-30 | 2016-01-07 | (주)메디톡스 | Composition pharmaceutique, pour le traitement de l'arthrose, comprenant la toxine botulique en tant qu'ingrédient actif, et méthode de traitement de l'arthrose à l'aide de celle-ci |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
EP3843777A4 (fr) * | 2018-08-28 | 2022-05-04 | Ira Sanders | Agents thérapeutiques pour la peau |
RU2732204C1 (ru) * | 2020-01-28 | 2020-09-14 | Частное учреждение образовательная организация высшего образования "Медицинский университет "Реавиз" | Способ лечения головных болей напряжения по Гурову-Левину |
KR20220046507A (ko) * | 2020-10-07 | 2022-04-14 | 주식회사 프로톡스 | 보툴리눔 독소의 진공 건조 방법 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4362731A (en) * | 1980-09-01 | 1982-12-07 | Sandoz Ltd. | Myotonolytic use of 4,5,6,7-tetrahydroisoxazolo [5,4-c] pyridin-3-ol and derivatives thereof |
US4664911A (en) | 1983-06-21 | 1987-05-12 | Board Of Regents, University Of Texas System | Immunotoxin conjugates employing toxin B chain moieties |
US5053005A (en) | 1989-04-21 | 1991-10-01 | Gary E. Borodic | Chemomodulation of curvature of the juvenile spine |
GB9022250D0 (en) * | 1990-10-12 | 1990-11-28 | Glaxo Group Ltd | Medicaments |
GB9120306D0 (en) * | 1991-09-24 | 1991-11-06 | Graham Herbert K | Method and compositions for the treatment of cerebral palsy |
WO1994000481A1 (fr) * | 1992-06-23 | 1994-01-06 | Associated Synapse Biologics | Composition pharmaceutique contenant un complexe de botulinum b |
EP0679090A1 (fr) * | 1993-01-15 | 1995-11-02 | Interactive Biologics Associates | Procede de traitement du syndrome de costen |
AU683275B2 (en) * | 1993-06-10 | 1997-11-06 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
DE69435254D1 (de) * | 1993-06-10 | 2009-12-31 | Allergan Inc | Behandlung von neuromusculaeren Störungen und Zuständen mit verschiedenen botulism Serotypen |
US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
AU688452B2 (en) * | 1993-12-28 | 1998-03-12 | Allergan, Inc. | Botulinum toxins for treating various disorders and associated pain |
US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
ATE292977T1 (de) * | 1994-05-09 | 2005-04-15 | William J Binder | Präsynaptische neurotoxine gegen migränekopfschmerzen |
JP2001104991A (ja) * | 1999-10-12 | 2001-04-17 | Toyoaki Kubota | 循環水の有機質除去剤 |
-
1994
- 1994-12-16 AU AU15162/95A patent/AU688452B2/en not_active Ceased
- 1994-12-16 DE DE69435276T patent/DE69435276D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69435321T patent/DE69435321D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69433394T patent/DE69433394T3/de not_active Expired - Lifetime
- 1994-12-16 EP EP04019048A patent/EP1488803B1/fr not_active Revoked
- 1994-12-16 ES ES04019047T patent/ES2247575T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP04000166A patent/EP1421948B1/fr not_active Expired - Lifetime
- 1994-12-16 ES ES05018368T patent/ES2334357T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69427869T patent/DE69427869T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES08017803T patent/ES2347384T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP05018367A patent/EP1600163B1/fr not_active Expired - Lifetime
- 1994-12-16 ES ES04019046T patent/ES2332905T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69434511T patent/DE69434511T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES00203294T patent/ES2246800T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES07002714T patent/ES2309973T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE122009000038C patent/DE122009000038I1/de active Pending
- 1994-12-16 DE DE69434443T patent/DE69434443T2/de not_active Revoked
- 1994-12-16 EP EP01118792A patent/EP1147775B1/fr not_active Expired - Lifetime
- 1994-12-16 EP EP05017284A patent/EP1602379A1/fr not_active Withdrawn
- 1994-12-16 EP EP97200028A patent/EP0770395B1/fr not_active Expired - Lifetime
- 1994-12-16 DE DE69434535T patent/DE69434535T2/de not_active Revoked
- 1994-12-16 EP EP07002714A patent/EP1790352B1/fr not_active Expired - Lifetime
- 1994-12-16 DE DE69435330T patent/DE69435330D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES03015589T patent/ES2242126T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP04018914A patent/EP1486214A1/fr not_active Withdrawn
- 1994-12-16 DE DE69435116T patent/DE69435116D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES95906674T patent/ES2159624T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP99203735A patent/EP1010431B2/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002682117A patent/CA2682117A1/fr not_active Abandoned
- 1994-12-16 ES ES05018367T patent/ES2339865T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES97200028T patent/ES2163090T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES99203735T patent/ES2237033T5/es not_active Expired - Lifetime
- 1994-12-16 DE DE69434610T patent/DE69434610T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP01118793A patent/EP1147776B1/fr not_active Expired - Lifetime
- 1994-12-16 DE DE122008000043C patent/DE122008000043I1/de active Pending
- 1994-12-16 EP EP00203421A patent/EP1103267B1/fr not_active Revoked
- 1994-12-16 DE DE69435243T patent/DE69435243D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69428813T patent/DE69428813T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP04019047A patent/EP1477183B1/fr not_active Revoked
- 1994-12-16 DE DE69435270T patent/DE69435270D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP08017803A patent/EP2027872B1/fr not_active Expired - Lifetime
- 1994-12-16 CA CA002180011A patent/CA2180011C/fr not_active Expired - Lifetime
- 1994-12-16 ES ES01118792T patent/ES2319860T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE122008000042C patent/DE122008000042I1/de active Pending
- 1994-12-16 DE DE69435249T patent/DE69435249D1/de not_active Expired - Lifetime
- 1994-12-16 EP EP03015589A patent/EP1366770B1/fr not_active Revoked
- 1994-12-16 ES ES00203421T patent/ES2223393T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP99203920A patent/EP1005867B2/fr not_active Expired - Lifetime
- 1994-12-16 EP EP06016208A patent/EP1757325B1/fr not_active Expired - Lifetime
- 1994-12-16 EP EP04019046A patent/EP1502600B1/fr not_active Expired - Lifetime
- 1994-12-16 EP EP00203294A patent/EP1072270B1/fr not_active Expired - Lifetime
- 1994-12-16 DE DE69435194T patent/DE69435194D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434319T patent/DE69434319T3/de not_active Expired - Lifetime
- 1994-12-16 EP EP05018368A patent/EP1598077B1/fr not_active Expired - Lifetime
- 1994-12-16 EP EP05016177A patent/EP1591129B1/fr not_active Expired - Lifetime
- 1994-12-16 WO PCT/US1994/014717 patent/WO1995017904A2/fr active IP Right Grant
- 1994-12-16 ES ES03015590T patent/ES2251651T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES05016177T patent/ES2340172T3/es not_active Expired - Lifetime
- 1994-12-16 EP EP95906674A patent/EP0737074B1/fr not_active Expired - Lifetime
- 1994-12-16 JP JP51812795A patent/JP3238154B2/ja not_active Expired - Lifetime
- 1994-12-16 EP EP03015590A patent/EP1366771B1/fr not_active Revoked
- 1994-12-16 DE DE69434540T patent/DE69434540T2/de not_active Expired - Lifetime
- 1994-12-16 EP EP05006665.3A patent/EP1563843B1/fr not_active Expired - Lifetime
- 1994-12-16 DE DE69435149T patent/DE69435149D1/de not_active Expired - Lifetime
- 1994-12-16 DE DE69434008T patent/DE69434008T2/de not_active Expired - Lifetime
- 1994-12-16 ES ES01118793T patent/ES2355491T3/es not_active Expired - Lifetime
- 1994-12-16 ES ES04019048T patent/ES2248780T3/es not_active Expired - Lifetime
- 1994-12-16 DE DE69435302T patent/DE69435302D1/de not_active Expired - Lifetime
- 1994-12-16 ES ES99203920T patent/ES2207910T5/es not_active Expired - Lifetime
-
2001
- 2001-06-11 HK HK01103981A patent/HK1033274A1/xx not_active IP Right Cessation
- 2001-07-16 JP JP2001214891A patent/JP2002097156A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214881A patent/JP2002104990A/ja active Pending
- 2001-07-16 JP JP2001214889A patent/JP2002087987A/ja active Pending
- 2001-07-16 JP JP2001214888A patent/JP2002068989A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214883A patent/JP2002114706A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214887A patent/JP2002087986A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214890A patent/JP2002087988A/ja active Pending
- 2001-07-16 JP JP2001214882A patent/JP2002104991A/ja not_active Withdrawn
- 2001-07-16 JP JP2001214884A patent/JP2002087984A/ja active Pending
- 2001-07-16 JP JP2001214886A patent/JP2002087985A/ja active Pending
- 2001-07-16 JP JP2001214885A patent/JP2002097145A/ja active Pending
-
2004
- 2004-09-28 HK HK04107484.4A patent/HK1064599A1/xx not_active IP Right Cessation
-
2005
- 2005-04-28 HK HK05103646A patent/HK1070831A1/xx not_active IP Right Cessation
- 2005-05-10 HK HK05103928A patent/HK1071071A1/xx not_active IP Right Cessation
- 2005-06-20 HK HK05105116.3A patent/HK1072375A1/xx not_active IP Right Cessation
-
2006
- 2006-01-26 JP JP2006017860A patent/JP2006160756A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017858A patent/JP2006160754A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017857A patent/JP2006160753A/ja not_active Withdrawn
- 2006-01-26 JP JP2006017859A patent/JP2006160755A/ja not_active Withdrawn
-
2007
- 2007-06-13 JP JP2007156168A patent/JP2007262086A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248745A patent/JP2008031176A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248742A patent/JP2008056683A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248739A patent/JP2008037877A/ja not_active Withdrawn
- 2007-09-26 JP JP2007248736A patent/JP2008056682A/ja not_active Withdrawn
- 2007-10-26 JP JP2007278365A patent/JP2008063339A/ja not_active Withdrawn
- 2007-11-14 HK HK07112425A patent/HK1106700A1/xx not_active IP Right Cessation
-
2008
- 2008-08-27 FR FR08C0034C patent/FR08C0034I1/fr active Active
-
2010
- 2010-05-19 JP JP2010115472A patent/JP2010202661A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115454A patent/JP2010209105A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115469A patent/JP2010202660A/ja not_active Withdrawn
- 2010-05-19 JP JP2010115462A patent/JP2010202659A/ja not_active Withdrawn
-
2012
- 2012-05-10 JP JP2012108652A patent/JP2012167115A/ja active Pending
- 2012-05-10 JP JP2012108658A patent/JP2012167116A/ja active Pending
- 2012-05-10 JP JP2012108656A patent/JP2012188433A/ja active Pending
- 2012-05-10 JP JP2012108662A patent/JP2012167117A/ja active Pending
- 2012-05-10 JP JP2012108649A patent/JP2012167114A/ja active Pending
- 2012-05-23 JP JP2012117085A patent/JP2012197287A/ja active Pending
- 2012-09-10 JP JP2012198070A patent/JP2013006865A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1072270B1 (fr) | Toxine de Botulinum pour le traitement de la dystonie | |
EP0702561B1 (fr) | Traitement des troubles et des pathologies neuromusculaires avec serotype e de botulinum | |
EP0702559B1 (fr) | Toxines de botulinum multiples utilisees dans le traitement de troubles et etats neuromusculaires | |
AU759750B2 (en) | Treatment of neuromuscular disorders and conditions with different botulinum serotype |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001020 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 737074 Country of ref document: EP |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): DE ES FR GB IT |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: CARLSON, STEVEN R. Inventor name: GRAYSTON, MICHAEL W. Inventor name: LEON, JUDITH M. Inventor name: AOKI, K. ROGER |
|
RIN1 | Information on inventor provided before grant (corrected) |
Inventor name: GRAYSTON, MICHAEL W. Inventor name: AOKI, K. ROGER Inventor name: CARLSON, STEVEN R. Inventor name: LEON, JUDITH M. |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7A 61K 38/48 A, 7A 61K 38/16 B, 7A 61P 21/02 B |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): DE ES FR GB IT |
|
AKX | Designation fees paid |
Designated state(s): DE ES FR GB IT |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: ALLERGAN, INC. |
|
17Q | First examination report despatched |
Effective date: 20030618 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RTI1 | Title (correction) |
Free format text: BOTULINUM TOXIN FOR TREATING DYSTONIA |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AC | Divisional application: reference to earlier application |
Ref document number: 0737074 Country of ref document: EP Kind code of ref document: P |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE ES FR GB IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2246800 Country of ref document: ES Kind code of ref document: T3 |
|
REF | Corresponds to: |
Ref document number: 69434511 Country of ref document: DE Date of ref document: 20060302 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1033274 Country of ref document: HK |
|
ET | Fr: translation filed | ||
PLBI | Opposition filed |
Free format text: ORIGINAL CODE: 0009260 |
|
PLAX | Notice of opposition and request to file observation + time limit sent |
Free format text: ORIGINAL CODE: EPIDOSNOBS2 |
|
26 | Opposition filed |
Opponent name: MERZ PHARMA GMBH & CO. KGAA Effective date: 20060718 |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
PLAB | Opposition data, opponent's data or that of the opponent's representative modified |
Free format text: ORIGINAL CODE: 0009299OPPO |
|
PLAF | Information modified related to communication of a notice of opposition and request to file observations + time limit |
Free format text: ORIGINAL CODE: EPIDOSCOBS2 |
|
R26 | Opposition filed (corrected) |
Opponent name: MERZ PHARMA GMBH & CO. KGAA Effective date: 20060718 |
|
PLBB | Reply of patent proprietor to notice(s) of opposition received |
Free format text: ORIGINAL CODE: EPIDOSNOBS3 |
|
PLBP | Opposition withdrawn |
Free format text: ORIGINAL CODE: 0009264 |
|
PLBD | Termination of opposition procedure: decision despatched |
Free format text: ORIGINAL CODE: EPIDOSNOPC1 |
|
PLBM | Termination of opposition procedure: date of legal effect published |
Free format text: ORIGINAL CODE: 0009276 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: OPPOSITION PROCEDURE CLOSED |
|
27C | Opposition proceedings terminated |
Effective date: 20071004 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20131227 Year of fee payment: 20 Ref country code: DE Payment date: 20131230 Year of fee payment: 20 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20131217 Year of fee payment: 20 Ref country code: ES Payment date: 20131226 Year of fee payment: 20 Ref country code: IT Payment date: 20131224 Year of fee payment: 20 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69434511 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R071 Ref document number: 69434511 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: PE20 Expiry date: 20141215 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20141215 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20150826 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF EXPIRATION OF PROTECTION Effective date: 20141217 |